- Home
- PRG vs RCUS Comparison
PRG vs RCUS Comparison
Compare PRG & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- RCUS
- Stock Information
- Founded
- PRG 2020
- RCUS 2015
- Country
- PRG United States
- RCUS United States
- Employees
- PRG N/A
- RCUS N/A
- Industry
- PRG Diversified Commercial Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- PRG Consumer Discretionary
- RCUS Health Care
- Exchange
- PRG Nasdaq
- RCUS Nasdaq
- Market Cap
- PRG 1.4B
- RCUS 1.2B
- IPO Year
- PRG N/A
- RCUS 2018
- Fundamental
- Price
- PRG $28.19
- RCUS $19.29
- Analyst Decision
- PRG Hold
- RCUS Buy
- Analyst Count
- PRG 6
- RCUS 8
- Target Price
- PRG $34.33
- RCUS $27.63
- AVG Volume (30 Days)
- PRG 414.9K
- RCUS 1.8M
- Earning Date
- PRG 10-22-2025
- RCUS 10-28-2025
- Dividend Yield
- PRG 1.86%
- RCUS N/A
- EPS Growth
- PRG 10.59
- RCUS N/A
- EPS
- PRG 3.96
- RCUS N/A
- Revenue
- PRG $2,507,179,000.00
- RCUS $240,000,000.00
- Revenue This Year
- PRG $1.28
- RCUS N/A
- Revenue Next Year
- PRG $0.64
- RCUS N/A
- P/E Ratio
- PRG $7.07
- RCUS N/A
- Revenue Growth
- PRG 3.71
- RCUS N/A
- 52 Week Low
- PRG $23.50
- RCUS $6.50
- 52 Week High
- PRG $49.90
- RCUS $22.11
- Technical
- Relative Strength Index (RSI)
- PRG 28.98
- RCUS 63.75
- Support Level
- PRG $29.22
- RCUS $18.32
- Resistance Level
- PRG $32.03
- RCUS $20.68
- Average True Range (ATR)
- PRG 1.24
- RCUS 1.26
- MACD
- PRG -0.29
- RCUS 0.02
- Stochastic Oscillator
- PRG 7.72
- RCUS 53.54
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.